EA201201329A1 - Новая композиция для лечения эссенциальной тромбоцитемии - Google Patents

Новая композиция для лечения эссенциальной тромбоцитемии

Info

Publication number
EA201201329A1
EA201201329A1 EA201201329A EA201201329A EA201201329A1 EA 201201329 A1 EA201201329 A1 EA 201201329A1 EA 201201329 A EA201201329 A EA 201201329A EA 201201329 A EA201201329 A EA 201201329A EA 201201329 A1 EA201201329 A1 EA 201201329A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
new composition
essential thrombocytemia
essential
thrombocytemia
Prior art date
Application number
EA201201329A
Other languages
English (en)
Other versions
EA027576B1 (ru
Inventor
Рудольф Видманн
Георг Штридер
Original Assignee
Аоп Орфан Фармацойтикальс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42732455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201329(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аоп Орфан Фармацойтикальс Аг filed Critical Аоп Орфан Фармацойтикальс Аг
Publication of EA201201329A1 publication Critical patent/EA201201329A1/ru
Publication of EA027576B1 publication Critical patent/EA027576B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к новой фармацевтической композиции без желудочного покрытия, содержащей гидрохлорид анагрелида в комбинации с не зависящим от рН полимером и фармацевтически приемлемой водорастворимой кислотой и ее применению для лечения эссенциальной тромбоцитемии.
EA201201329A 2010-03-25 2011-03-25 Новая композиция для лечения эссенциальной тромбоцитемии EA027576B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10157772 2010-03-25
PCT/EP2011/054628 WO2011117391A2 (en) 2010-03-25 2011-03-25 Novel composition for treatment of essential thrombocythemia

Publications (2)

Publication Number Publication Date
EA201201329A1 true EA201201329A1 (ru) 2013-02-28
EA027576B1 EA027576B1 (ru) 2017-08-31

Family

ID=42732455

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201329A EA027576B1 (ru) 2010-03-25 2011-03-25 Новая композиция для лечения эссенциальной тромбоцитемии

Country Status (23)

Country Link
US (4) US20130028945A1 (ru)
EP (1) EP2549983B1 (ru)
JP (1) JP5836357B2 (ru)
AU (1) AU2011231557B2 (ru)
BR (1) BR112012024239A2 (ru)
CA (1) CA2794237C (ru)
CY (1) CY1116396T1 (ru)
DK (1) DK2549983T3 (ru)
EA (1) EA027576B1 (ru)
ES (1) ES2535480T3 (ru)
HR (1) HRP20150410T1 (ru)
IL (1) IL222072A (ru)
ME (1) ME02118B (ru)
MX (1) MX2012011051A (ru)
NZ (1) NZ602366A (ru)
PL (1) PL2549983T3 (ru)
PT (1) PT2549983E (ru)
RS (1) RS53960B1 (ru)
SG (1) SG184227A1 (ru)
SI (1) SI2549983T1 (ru)
SM (1) SMT201500119B (ru)
UA (1) UA110933C2 (ru)
WO (1) WO2011117391A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535480T3 (es) * 2010-03-25 2015-05-12 Aop Orphan Pharmaceuticals Ag Nueva composición para el tratamiento de la trombocitemia esencial
US11324746B2 (en) 2014-12-22 2022-05-10 Arovella Therapeutics Limited Use of anagrelide for treating cancer
EP4183430A1 (en) 2021-11-18 2023-05-24 Koninklijke Philips N.V. Sensor arrangement for a breast pump device and breast pump device using the sensor arrangement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
ES2322896T3 (es) * 2002-04-29 2009-07-01 Supernus Pharmaceuticals, Inc. Formulaciones farmaceuticas con biodisponibilidad mejorada.
US7993654B2 (en) * 2002-12-23 2011-08-09 Beiersdorf Ag Self-adhesive polymer matrix containing sea algae extract
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
US20100056493A1 (en) * 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
ES2535480T3 (es) * 2010-03-25 2015-05-12 Aop Orphan Pharmaceuticals Ag Nueva composición para el tratamiento de la trombocitemia esencial

Also Published As

Publication number Publication date
EA027576B1 (ru) 2017-08-31
WO2011117391A2 (en) 2011-09-29
HRP20150410T1 (hr) 2015-06-05
CY1116396T1 (el) 2017-02-08
SI2549983T1 (sl) 2015-06-30
JP5836357B2 (ja) 2015-12-24
US20180028538A1 (en) 2018-02-01
DK2549983T3 (da) 2015-06-01
WO2011117391A3 (en) 2012-01-19
AU2011231557B2 (en) 2016-05-26
RS53960B1 (en) 2015-08-31
EP2549983A2 (en) 2013-01-30
CA2794237A1 (en) 2011-09-29
US9782413B2 (en) 2017-10-10
SMT201500119B (it) 2015-07-09
US20150086637A1 (en) 2015-03-26
UA110933C2 (uk) 2016-03-10
EP2549983B1 (en) 2015-03-04
MX2012011051A (es) 2013-01-29
JP2013523616A (ja) 2013-06-17
PT2549983E (pt) 2015-06-17
PL2549983T3 (pl) 2015-08-31
US20170035768A1 (en) 2017-02-09
CA2794237C (en) 2017-09-26
US20130028945A1 (en) 2013-01-31
BR112012024239A2 (pt) 2016-07-12
ME02118B (me) 2015-10-20
IL222072A (en) 2017-12-31
AU2011231557A1 (en) 2012-10-04
ES2535480T3 (es) 2015-05-12
NZ602366A (en) 2014-08-29
SG184227A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
EA201270722A1 (ru) Формы рифаксимина и их применение
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
EA201201509A1 (ru) Фармацевтические составы, содержащие пиоглитазон и линаглиптин
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
MX2013004061A (es) Analogos de ciclosporina.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201390799A1 (ru) Триазолопиридины
MX2013004062A (es) Analogos de ciclosporina.
EA201171414A1 (ru) Ингибиторы белков семейства iap
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
TR201100150A2 (tr) Suda çözünür dozaj formları
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
BR112012016736A2 (pt) composição , formulação farmacêutica e uso da composição"

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU